- Patent Title: Anti-Kv1.3 antibodies, and methods of production and use thereof
-
Application No.: US16098670Application Date: 2017-05-02
-
Publication No.: US11597763B2Publication Date: 2023-03-07
- Inventor: Paul A. Colussi , Janna Bednenko , Yelena Bisharyan , Ashot Papoyan , Joanna Cardarelli , Theodore G. Clark , Douglas Kahn , Lore Mariën , Bas Van Der Woning , Hans De Haard , William D. Harriman , Ellen J. Collarini , Alka Agrawal
- Applicant: Tetragenetics, Inc.
- Applicant Address: US MA Arlington
- Assignee: Tetragenetics, Inc.
- Current Assignee: Tetragenetics, Inc.
- Current Assignee Address: US MA Arlington
- Agency: Wolf, Greenfield & Sacks, P.C.
- International Application: PCT/US2017/030612 WO 20170502
- International Announcement: WO2017/192567 WO 20171109
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P37/06 ; C07K16/44

Abstract:
Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.
Public/Granted literature
- US20190144538A1 ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF Public/Granted day:2019-05-16
Information query